Supplemental ultrasound screening in patients with a history of lobular neoplasia

Kanchan Ashok Phalak, Denái Rochelle Milton, Wei Tse Yang, Therese Bartholomew Bevers, Basak Dogan

Research output: Contribution to journalArticle

Abstract

To investigate the role of ultrasound (US) screening as an adjunct to annual mammography (M) in breast cancer detection in women with a history of lobular neoplasia (LN) diagnosed following core needle or excisional biopsy. A retrospective review of our database was performed between 11/2006 and 11/2011 to identify patients diagnosed with LN, and underwent annual screening. Patients with a lifetime risk >20% per risk modeling were excluded. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and cancer detection rate (CDR) of each screening test were identified. Cancer type and detection modality were recorded. A total of 100 patients who had M and/or US screening were included. Mean patient age was 54.7 years (range 33-83). All 100 patients underwent a mean of 3.9 rounds of screening M and 93 (93%) received US screening (mean 3.3 rounds). Of 93 patients who received both M and US screening, 12 (13%) were diagnosed with breast cancer. Mammographic CDR was 4%. Incremental US CDR was 6.5%. The sensitivity, specificity, and NPV for M screening alone was 33% (10%, 65%), 77% (67%, 85%), and 89% (80%, 95%), respectively. US and mammography screening had a combined sensitivity: 83% (52%, 98%), Specificity: 72% (62%, 81%), NPV: 97% (89%, 100%). Supplemental US screening resulted in a significant increase in sensitivity, yielding 6.5% incremental CDR in this high-risk patient subgroup that does not fulfill ACS high-risk MRI screening criteria.

Original languageEnglish (US)
JournalBreast Journal
DOIs
StateAccepted/In press - Jan 1 2019
Externally publishedYes

Fingerprint

Neoplasms
Mammary Ultrasonography
Breast Neoplasms
Sensitivity and Specificity
Mammography
Needles
Databases
Biopsy

Keywords

  • breast ultrasound
  • lobular neoplasia
  • ultrasound-guided needle biopsy

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Cite this

Supplemental ultrasound screening in patients with a history of lobular neoplasia. / Phalak, Kanchan Ashok; Milton, Denái Rochelle; Yang, Wei Tse; Bevers, Therese Bartholomew; Dogan, Basak.

In: Breast Journal, 01.01.2019.

Research output: Contribution to journalArticle

Phalak, Kanchan Ashok ; Milton, Denái Rochelle ; Yang, Wei Tse ; Bevers, Therese Bartholomew ; Dogan, Basak. / Supplemental ultrasound screening in patients with a history of lobular neoplasia. In: Breast Journal. 2019.
@article{b1d2fd7d6f9a490e85c661377e213185,
title = "Supplemental ultrasound screening in patients with a history of lobular neoplasia",
abstract = "To investigate the role of ultrasound (US) screening as an adjunct to annual mammography (M) in breast cancer detection in women with a history of lobular neoplasia (LN) diagnosed following core needle or excisional biopsy. A retrospective review of our database was performed between 11/2006 and 11/2011 to identify patients diagnosed with LN, and underwent annual screening. Patients with a lifetime risk >20{\%} per risk modeling were excluded. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and cancer detection rate (CDR) of each screening test were identified. Cancer type and detection modality were recorded. A total of 100 patients who had M and/or US screening were included. Mean patient age was 54.7 years (range 33-83). All 100 patients underwent a mean of 3.9 rounds of screening M and 93 (93{\%}) received US screening (mean 3.3 rounds). Of 93 patients who received both M and US screening, 12 (13{\%}) were diagnosed with breast cancer. Mammographic CDR was 4{\%}. Incremental US CDR was 6.5{\%}. The sensitivity, specificity, and NPV for M screening alone was 33{\%} (10{\%}, 65{\%}), 77{\%} (67{\%}, 85{\%}), and 89{\%} (80{\%}, 95{\%}), respectively. US and mammography screening had a combined sensitivity: 83{\%} (52{\%}, 98{\%}), Specificity: 72{\%} (62{\%}, 81{\%}), NPV: 97{\%} (89{\%}, 100{\%}). Supplemental US screening resulted in a significant increase in sensitivity, yielding 6.5{\%} incremental CDR in this high-risk patient subgroup that does not fulfill ACS high-risk MRI screening criteria.",
keywords = "breast ultrasound, lobular neoplasia, ultrasound-guided needle biopsy",
author = "Phalak, {Kanchan Ashok} and Milton, {Den{\'a}i Rochelle} and Yang, {Wei Tse} and Bevers, {Therese Bartholomew} and Basak Dogan",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/tbj.13191",
language = "English (US)",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Supplemental ultrasound screening in patients with a history of lobular neoplasia

AU - Phalak, Kanchan Ashok

AU - Milton, Denái Rochelle

AU - Yang, Wei Tse

AU - Bevers, Therese Bartholomew

AU - Dogan, Basak

PY - 2019/1/1

Y1 - 2019/1/1

N2 - To investigate the role of ultrasound (US) screening as an adjunct to annual mammography (M) in breast cancer detection in women with a history of lobular neoplasia (LN) diagnosed following core needle or excisional biopsy. A retrospective review of our database was performed between 11/2006 and 11/2011 to identify patients diagnosed with LN, and underwent annual screening. Patients with a lifetime risk >20% per risk modeling were excluded. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and cancer detection rate (CDR) of each screening test were identified. Cancer type and detection modality were recorded. A total of 100 patients who had M and/or US screening were included. Mean patient age was 54.7 years (range 33-83). All 100 patients underwent a mean of 3.9 rounds of screening M and 93 (93%) received US screening (mean 3.3 rounds). Of 93 patients who received both M and US screening, 12 (13%) were diagnosed with breast cancer. Mammographic CDR was 4%. Incremental US CDR was 6.5%. The sensitivity, specificity, and NPV for M screening alone was 33% (10%, 65%), 77% (67%, 85%), and 89% (80%, 95%), respectively. US and mammography screening had a combined sensitivity: 83% (52%, 98%), Specificity: 72% (62%, 81%), NPV: 97% (89%, 100%). Supplemental US screening resulted in a significant increase in sensitivity, yielding 6.5% incremental CDR in this high-risk patient subgroup that does not fulfill ACS high-risk MRI screening criteria.

AB - To investigate the role of ultrasound (US) screening as an adjunct to annual mammography (M) in breast cancer detection in women with a history of lobular neoplasia (LN) diagnosed following core needle or excisional biopsy. A retrospective review of our database was performed between 11/2006 and 11/2011 to identify patients diagnosed with LN, and underwent annual screening. Patients with a lifetime risk >20% per risk modeling were excluded. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and cancer detection rate (CDR) of each screening test were identified. Cancer type and detection modality were recorded. A total of 100 patients who had M and/or US screening were included. Mean patient age was 54.7 years (range 33-83). All 100 patients underwent a mean of 3.9 rounds of screening M and 93 (93%) received US screening (mean 3.3 rounds). Of 93 patients who received both M and US screening, 12 (13%) were diagnosed with breast cancer. Mammographic CDR was 4%. Incremental US CDR was 6.5%. The sensitivity, specificity, and NPV for M screening alone was 33% (10%, 65%), 77% (67%, 85%), and 89% (80%, 95%), respectively. US and mammography screening had a combined sensitivity: 83% (52%, 98%), Specificity: 72% (62%, 81%), NPV: 97% (89%, 100%). Supplemental US screening resulted in a significant increase in sensitivity, yielding 6.5% incremental CDR in this high-risk patient subgroup that does not fulfill ACS high-risk MRI screening criteria.

KW - breast ultrasound

KW - lobular neoplasia

KW - ultrasound-guided needle biopsy

UR - http://www.scopus.com/inward/record.url?scp=85060657240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060657240&partnerID=8YFLogxK

U2 - 10.1111/tbj.13191

DO - 10.1111/tbj.13191

M3 - Article

C2 - 30675929

AN - SCOPUS:85060657240

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

ER -